Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063021 | 0.85 | NLRP3 (0.47) | CYP4F2CYP4A11ALDH1A1NLRP3KMT2A | |
| SCHEMBL5379790 | 0.85 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1GAANLRP3 | |
| SCHEMBL14874345 | 0.85 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1GAANLRP3 | |
| SCHEMBL490337 | 0.84 | CYP4F2 (0.57) | CYP4F2CYP4A11ALDH1A1GAAKMT2A | |
| SCHEMBL1151562 | 0.83 | CYP4F2 (0.69) | CYP4F2CYP4A11ALDH1A1GAANLRP3 | |
| SCHEMBL7293339 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11ALDH1A1GAANLRP3 | |
| SCHEMBL17743633 | 0.82 | POLB (0.49) | ALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL30798905 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL27859213 | 0.81 | CYP4F2 (0.57) | CYP4F2CYP4A11ALDH1A1GAANLRP3 | |
| SCHEMBL14874376 | 0.81 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1GAANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | CYP4F2 2767/4885CYP4A11 3927/4885ALDH1A1 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.